Literature DB >> 6604111

Epidermal cell-induced generation of cytotoxic T-lymphocyte responses against alloantigens or TNP-modified syngeneic cells: requirement for Ia-positive Langerhans cells.

H Pehamberger, L A Stingl, S Pogantsch, G Steiner, K Wolff, G Stingl.   

Abstract

The role of epidermal cells (EC) in the activation of T-cell proliferation is well established. In this study we asked whether EC can provide a stimulus resulting in the generation of genetically restricted T-cell cytotoxicity. For this purpose, C57Bl/6 or C3H/He highly purified, accessory cell-depleted responder splenic T lymphocytes, were stimulated in 5-day cell-mediated cytotoxicity cultures with mitomycin C-treated allogeneic or trinitrophenyl (TNP)-modified syngeneic EC, or, for control purposes, with unfractionated spleen cells (SC). Untreated and complement (C')-treated EC induced strong cytotoxic T lymphocyte (CTL) activity in highly purified allogeneic T cells and, in analogy, TNP-modified EC led to the generation of TNP-self CTL, as tested in 4-h 51Cr release assays against allogeneic or TNP-modified syngeneic EC or SC targets. These cytotoxic responses were comparable in magnitude to those seen with allogeneic or TNP-modified syngeneic SC stimulators. In contrast, alloreactive or TNP-self CTL responses were not generated when stimulating EC were depleted of Langerhans cells by pretreatment with anti-Ia monoclonal antibodies plus C' or, for control purposes, when highly purified T-cell stimulators were used. These results demonstrate that EC induce the generation of alloreactive and TNP-self CTL in the absence of Ia-positive splenic accessory cells and that Ia-bearing Langerhans cell are required for this process to occur.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604111     DOI: 10.1111/1523-1747.ep12517984

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

Review 1.  Immunology of corneal transplantation.

Authors:  W H Constad; K Taraschanskiy
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 2.  Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells.

Authors:  M B Teunissen
Journal:  Histochem J       Date:  1992-10

3.  MHC class II antigen expression in normal human epidermis.

Authors:  M M Carr; E McVittie; K Guy; D J Gawkrodger; J A Hunter
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

4.  Turnover and kinetics of epidermal Langerhans cells and their dendritic precursor cells in experimental contact dermatitis. A correlated ultrastructural-morphometric and immunohistochemical evaluation.

Authors:  G Kolde
Journal:  Arch Dermatol Res       Date:  1996-04       Impact factor: 3.017

5.  Neoantigen Expression in Steady-State Langerhans Cells Induces CTL Tolerance.

Authors:  Helen Strandt; Douglas Florindo Pinheiro; Daniel H Kaplan; Dagmar Wirth; Iris Karina Gratz; Peter Hammerl; Josef Thalhamer; Angelika Stoecklinger
Journal:  J Immunol       Date:  2017-07-24       Impact factor: 5.422

Review 6.  Role of epidermal Langerhans cells in viral infections.

Authors:  E Sprecher; Y Becker
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

Review 7.  Immunologic roles of hyaluronan.

Authors:  Mark E Mummert
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 8.  The evolving function of Langerhans cells in adaptive skin immunity.

Authors:  Botond Z Igyarto; Daniel H Kaplan
Journal:  Immunol Cell Biol       Date:  2010-03-16       Impact factor: 5.126

9.  Immunoelectron microscopic analysis of Ia antigen expression in rat skin during limb allograft rejection.

Authors:  M Mohtai; Y Sugioka; T Hotokebuchi; K Arai; A Hirana; K Wasano; N Kaibara
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

10.  Langerhans cells in human middle ear cholesteatomas.

Authors:  W Y Chao; Y T Jin; C C Huang
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.